US Market study: Early Lung Cancer Diagnosis using Artificial Intelligence and Big Data

Optellum’s vision is to enable earlier and more confident cancer diagnosis and treatment by using Artificial

Intelligence (AI) and Deep Learning to unlock new insights in huge image databases. Our first product that will

target early detection of lung cancer, the World’s most common and lethal cancer.

The US market holds the biggest potential due to established reimbursement for lung-cancer screening.

However, it presents special challenges, due to 1) Complex FDA regulatory regime 2) High data variability,

combined with legal hurdles for accessing patient data for algorithm training 3) Different customer needs.

This project will enable us to establish partnerships with US hospitals that will help us accelerate US market

entry by 1) Developing FDA regulatory strategy 2) Creating a roadmap for the training and validation of our

algorithms on US patient datasets 3) Developing product specifications that fulfil US customer needs.